Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Verified
Porto, Portugal
Not recruiting
Pharmacokinetics of Nicorandil 40 mg Extended‑Release Capsules in Healthy Volunteers Under Fasting and Fed Conditions
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
The study examines how the body handles a single dose of Nicorandil 40 mg formulated as an extended-release capsule. This medication is taken by mouth and is designed to release the drug slowly over time. The trial enrolls healthy volunteers who do not have any known medical condition.
The purpose is to characterize and compare the pharmacokinetics of the drug and its breakdown product N-(2-hydroxyethyl) nicotinamide when the dose is taken under fasting conditions and after a meal (fed conditions). Participants receive the capsule once, then later receive the same capsule under the opposite condition, allowing each person to serve as their own comparison. Throughout the study, vital signs, heart rhythm checks, and laboratory tests are performed, and any side effects that appear are recorded.
The research process
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
12 criteria
- Signed a free written informed consent form and dated it before any study procedures (this means you understand the study and agree to take part).
- Do not use tobacco or nicotine products, or have stopped using them for at least 3 months before the screening (non‑smoker or ex‑smoker).
- Agree to follow all study procedures and any restrictions that are required.
- If you are female, you must either be unable to become pregnant, or if you can become pregnant you must agree to use a highly effective birth‑control method starting at least 8 weeks before the first study period and continue until the study ends.
- Be between 18 and 55 years old (inclusive) at the time you sign the consent form.
- Have a body mass index (BMI) between 18.0 and 31.0 kg/m² (BMI is a simple calculation that relates your weight to your height).
- Have no important medical conditions in your medical history that could affect the study.
- Have no important findings on a physical examination.
- Have normal vital signs such as blood pressure and heart rate (no important abnormalities).
- Have a normal 12‑lead ECG (a test that records the electrical activity of the heart).
- Have normal results on routine laboratory tests (no important abnormalities).
- Test negative for infections: HIV antibodies, Hepatitis B surface antigen, and Hepatitis C antibodies (these tests check for specific viruses).
Who cannot join the trial?
28 criteria
- Allergy to the study drug or any of its ingredients – you cannot take part if you are known to have a hypersensitivity (allergic) reaction to nicorandil or any substance used in the capsule.
- Very low blood pressure – if your systolic blood pressure (the top number) is less than 95 mmHg or your diastolic blood pressure (the bottom number) is less than 45 mmHg.
- Elevated liver enzymes – if blood tests show that alanine aminotransferase (ALT) or aspartate aminotransferase (AST) are above the normal range, indicating possible liver problems.
- Poor kidney function – if your estimated creatinine clearance (a measure of kidney filtering ability calculated with the Cockcroft‑Gault formula) is below the normal lower limit.
- Positive drug or alcohol test – if tests detect illegal drugs or recent alcohol use.
- Recent long‑acting medication injection or implant – if you have received a depot injection or implanted drug (other than contraceptives) in the past 6 months.
- High alcohol consumption – drinking more than 14 units per week for men or more than 7 units per week for women in the past 6 months.
- Heavy caffeine intake – consuming more than about 500 mg of caffeine (found in coffee, tea, cola, sodas, chocolate, etc.) each day.
- Recent participation in other clinical studies – if you have been in any clinical trial in the past 2 months.
- Too many recent clinical studies – if you have taken part in more than two clinical trials in the past 12 months.
- Recent blood donation or large blood loss – donating at least 450 mL of blood or having a procedure called plasmapheresis within the past 2 months.
- Severe allergy to any other medication – known history of a serious hypersensitivity reaction to drugs other than the study drug.
- Difficulty fasting or special diet restrictions – if you cannot fast or have dietary restrictions (e.g., lactose intolerance, vegan, low‑fat, low‑sodium) that would interfere with the study meals.
- Inadequate veins for blood draws – if veins in both arms are not suitable for inserting an intravenous needle.
- Problems swallowing capsules – if you have difficulty swallowing pills or capsules.
- Pregnancy – if you are a woman who could become pregnant and test positive for pregnancy.
- Breast‑feeding – if you are currently nursing a baby.
- Any condition the doctor feels makes you unsuitable – the investigator may decide you are not appropriate for the study for any reason.
- Recent illness or treatment that could affect safety or drug behavior – any disease, condition, or therapy that might put you at risk or change how the drug works.
- Use of vitamins, supplements, or herbal products within 2 weeks – unless the doctor believes they will not interfere with the study drug.
- Use of certain heart medications – taking phosphodiesterase‑5 inhibitors (such as sildenafil, tadalafil, vardenafil) or soluble guanylate cyclase stimulants (such as riociguat) within the past week.
- Medical problems that could affect drug absorption or safety – conditions affecting the stomach, intestines, kidneys, liver, or past surgeries (like gallbladder removal or stomach surgery) that might change how the drug is processed.
- Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency – a hereditary enzyme deficiency that can cause red‑blood‑cell problems with certain drugs.
- History of severe low blood pressure or shock – past episodes of very low blood pressure or circulatory collapse.
- History of serious heart problems – such as acute pulmonary edema (fluid in the lungs), heart failure, coronary artery disease, or a heart attack (myocardial infarction).
- History of fainting or drops in blood pressure when standing – includes orthostatic hypotension, collapse, fainting (syncope), or vasovagal reactions.
- Recent substance or alcohol abuse – misuse of drugs or alcohol within the past 2 years.
- Use of contact lenses – wearing contact lenses during the study period.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Nicorandil is a medication taken by mouth in the form of a prolonged‑release capsule. In this study, a single dose was given to healthy volunteers to see how the drug and its breakdown product move through the body. The researchers looked at how quickly it is absorbed, how long it stays in the bloodstream, and how food might change these processes. This helps scientists understand the best way to use the medicine and how meals could affect its action.
What is already known about the treatment
Nicorandil - The drug is taken by mouth as a prolonged‑release capsule, 40 mg, designed to dissolve slowly after swallowing. Nicorandil is an approved medication that is widely used and well described in medical literature. It is mainly prescribed to relieve chest pain (angina) by opening blood vessels and releasing nitric oxide, which relaxes the heart’s muscle and improves blood flow at the molecular level. It belongs to the class of vasodilators and potassium‑channel activators.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-506085-31-00Protocol codeAUX-PNI19-PK01Estimated enrolment16 patientsSponsorAuxilius Pharma Sp. z o.o.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?